Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will host a conference call and webcast on November 12, 2024 at 4:30 pm ET to provide a business update and report third quarter 2024 financial results. The conference call can be accessed toll-free at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A live webcast will be available through the company's investor relations section, with a replay accessible for 90 days on Corvus' website.
Positive
- None.
Negative
- None.
News Market Reaction – CRVS
On the day this news was published, CRVS declined 4.88%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
BURLINGAME, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 12, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2024 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) report Q3 2024 earnings?
How can I access Corvus Pharmaceuticals (CRVS) Q3 2024 earnings call?
How long will Corvus Pharmaceuticals (CRVS) Q3 2024 earnings call replay be available?
